Your session is about to expire
← Back to Search
Combination Therapy for Mantle Cell Lymphoma
Study Summary
This trial is studying a combination of rituximab, bortezomib, bendamustine, and lenalidomide to see how well it works compared with rituximab and bendamustine, followed by rituximab alone or with lenalidomide, in treating mantle cell lymphoma.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2011 Phase 3 trial • 224 Patients • NCT01126541Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I can take care of myself and perform daily activities.People with HIV can participate if they meet specific requirements.My lymphoma is confirmed as mantle cell type with specific genetic markers.I have had a blood clot and take medication to prevent another.I do not have severe heart problems or uncontrolled chest pain.My HIV responds to treatment.I do not have severe numbness or pain in my hands or feet.I have no cancer history except for certain skin cancers, cervical cancer in situ, or any cancer cured over 5 years ago.I am willing to take antiretroviral therapy if needed.I am on HIV medication but not taking zidovudine or stavudine.I am not allergic to bortezomib, boron, or mannitol.I am not in another clinical trial or taking experimental drugs.I agree to take medicine to prevent a specific type of pneumonia during and after my treatment.Your CD4 cell count was less than 300 cells/mm³ when you were diagnosed with lymphoma.My kidneys are functioning well enough, with a creatinine clearance rate of at least 30 mL/min.I agree to use a condom during sex if my partner can have children, even though I've had a vasectomy.I have never had an AIDS-defining illness.Your bilirubin levels in the blood are not more than twice the normal limit.You need to have a negative pregnancy test.I do not have a serious illness or mental health condition that could affect my study participation.I am on Arms G or H, have no history of blood clots, and take daily aspirin for clot prevention.Your white blood cell count is at least 1,500 per microliter, unless it's caused by a specific type of bone marrow issue.I cannot take aspirin and am on a blood thinner like heparin or warfarin.I am willing and able to take medication to prevent blood clots.Patients must have at least one specific sign of their disease that can be measured.My cancer has not spread to my brain or spinal cord.Your platelet count should be at least 100,000 per microliter, unless there is a problem with your bone marrow.Your liver enzymes (AST/ALT) are not more than double the normal level.I have no cancer history except for certain skin cancers, cervical cancer in situ, or any cancer cured over 5 years ago.I have not had treatment for MCL, except for a short steroid course.My disease was confirmed by CT scan or similar, not just a PET scan.My lymphoma is only in my liver and can be measured.
- Group 1: Arm C
- Group 2: Arm H
- Group 3: Arm G
- Group 4: Arm A
- Group 5: Arm B
- Group 6: Arm D
- Group 7: Arm E
- Group 8: Arm F
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What clinical indications would necessitate the use of rituximab?
"Rituximab is the preferred medicine for treating diffuse large b-cell lymphoma (dlbcl). It has also been used to ameliorate symptoms related to conditions like prior systemic chemotherapy regimens, polyangium and certain types of B cell lymphomas."
How many individuals have been recruited for the experimental inquiry?
"Currently, this particular experiment is not enrolling patients. According to the records on clinicaltrials.gov, it was initially posted in May of 2012 and last updated in August of 2020. Nevertheless, there are 1,741 trials actively accepting participants with lymphoma as well as 725 studies for rituximab seeking volunteers at this time."
Has the Federal Drug Administration approved rituximab?
"Despite being at Phase 2 of clinical trials, there is prior evidence for rituximab's safety which led to it receiving a score of 2."
How many facilities are presently engaged in this research endeavor?
"In addition to many other sites, Providence Portland Medical Center in Portland, Oregon, Oncology Hematology Care Inc-Mercy West in Cincinnati, Ohio, and Mary Greeley Medical Center in Ames Hawaii are all currently taking part in this clinical trial."
Does this investigation accept participants above the age of fifty?
"This trial requires that all participants are at least 60 years of age and not above 120."
Are there any precedents of successful experimentation with rituximab?
"Currently, 725 clinical experiments are in progress to research rituximab with 160 of them being in their terminal stage. Although a portion of these trials is centered around Joliet, Illinois, there are 28017 venues worldwide conducting studies for this drug."
Are there any remaining vacancies in this research project?
"Per information on clinicaltrials.gov, this research study is not presently recruiting participants even though it was initially posted in May 2012 and last modified on August 10th 2022. Nevertheless, there are 2466 alternate trials that have open recruitment at the time of writing."
Who is eligible to be included in this exploration?
"Suitable candidates for this lymphoma trial should be aged between 60 and 120 years old. Currently, 373 individuals are required to join the study."
Share this study with friends
Copy Link
Messenger